Caitlin Adamowicz, NP
Nurse Practitioner · Scottsdale, AZNPI 1104583152
Payments from drug & device makers
Across 253 payments — averaging $23.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$1K
- Novo Nordisk$883
- Lilly USA, LLC$711
- Medtronic$551
- Sanofi-aventis U.S. LLC$409
- Amgen$393
- plus $2K from 26 others
What the payments were for
- Food & beverage$5,933100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 31 | $1,220 |
| Novo Nordisk | 78 | $883 |
| Lilly USA, LLC | 38 | $711 |
| Medtronic | 6 | $551 |
| Sanofi-aventis U.S. LLC | 16 | $409 |
| Amgen(2 entities) | 10 | $393 |
| Abbott | 4 | $190 |
| Tandem Diabetes Care, Inc. | 2 | $148 |
| AbbVie | 7 | $140 |
| BETA Bionics, Inc. | 1 | $129 |
| Xeris Pharmaceuticals, Inc. | 7 | $127 |
| Radius Health, Inc. | 6 | $127 |
| Mannkind Corporation | 6 | $115 |
| Insulet Corporation | 5 | $104 |
| Dexcom, Inc. | 4 | $83 |
| Amneal Pharmaceuticals LLC | 3 | $61 |
| Ultragenyx Pharmaceutical Inc. | 3 | $61 |
| Intuity Medical Inc | 3 | $55 |
| Ascensia Diabetes Care US Inc. | 2 | $46 |
| Antares Pharma, Inc. | 3 | $45 |
| Recordati_rare_diseases_inc. | 2 | $45 |
| AstraZeneca | 2 | $45 |
| Currax Pharmaceuticals LLC | 3 | $41 |
| Boehringer Ingelheim | 2 | $38 |
| Bayer | 2 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Renalytix AI, Inc. | 1 | $22 |
| Rhythm Pharmaceuticals, Inc. | 1 | $21 |
| Novartis | 1 | $21 |
| Globus Medical | 1 | $19 |
| Cequr Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$684
- iLet Bionic Pancreas$387
- MINIMED 770G$311
- Prolia$244
- FREESTYLE LIBRE 3$149
- INTELLIS ADAPTIVESTIM$139
- t:slim X2 Insulin Pump with Control-IQ$136
- Ozempic$125
- JARDIANCE$117
- TOUJEO$116
- SOLIQUA 100/33$102
How this compares
$5,945 in reported general payments places this provider in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 213 | $308,626 |
| OzempicSemaglutide | 140 | $206,119 |
| JardianceEmpagliflozin | 61 | $76,830 |
| TrulicityDulaglutide | 33 | $62,470 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 32 | $29,054 |
| FarxigaDapagliflozin Propanediol | 23 | $28,694 |
| Teriparatide | 14 | $24,901 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $24,087 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $17,994 |
| Humalog Kwikpen U-100Insulin Lispro | 37 | $16,216 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $15,964 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 14 | $15,223 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $14,754 |
| Novolog FlexpenInsulin Aspart | 36 | $11,460 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $10,969 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $711 | $376,666267 claims |
| Novo NordiskOzempic | $883 | $206,119140 claims |
| Boehringer IngelheimJardiance | $38 | $76,83061 claims |
| AstraZenecaFarxiga | $45 | $28,69423 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $409 | $14,75417 claims |
| AbbVieSynthroid | $140 | $1,99417 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $61 | $1,359144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,719 nurse practitioner providers in Arizona.
Other nurse practitioner in Scottsdale
- Kristen HerzogScottsdale$162K
- Kelley RoneScottsdale$29K
- Jill StudyScottsdale$24K
- Jennifer BarbosaScottsdale$21K
- Jessica LoweryScottsdale$16K
- Ronald OrdasScottsdale$8K
- Theresa LongoScottsdale$8K
- Samantha DeberryScottsdale$8K
- Meagan GruwellScottsdale$7K
- Ann MooreGlendale$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.